Clinical Trial: Efficacy and Safety of Immune Checkpoint Inhibitors for Refractory Opportunistic Infections in AIDS

U.S., May 13 -- ClinicalTrials.gov registry received information related to the study (NCT07579247) titled 'Efficacy and Safety of Immune Checkpoint Inhibitors for Refractory Opportunistic Infections in AIDS' on May 06.

Brief Summary: This prospective, single-arm, open-label study aims to evaluate the efficacy and safety of a PD-1 inhibitor (Sintilimab) combined with standard anti-infective therapy in patients with advanced HIV disease (AHD) who are suffering from refractory opportunistic infections (OIs).

Despite effective antiretroviral therapy (ART), some HIV patients develop severe, hard-to-treat infections (such as CMV, PCP, Tuberculosis, etc.) that do not respond to standard antimicrobial treatments. This is often due to a condition...